Angle Share Discussion Threads

[waterloo01] 04/4/2024 15:28

The Role of Circulating Tumor Cells as a Liquid Biopsy for Cancer: Advances, Biology, Technical Challenges, and Clinical Relevance

In conclusion, CTCs represent a pivotal element in the evolving landscape of cancer management. Their potential to transform cancer diagnosis, prognosis, and therapy is immense, heralding a future where cancer treatment is more dynamic, precise, and patient-centric. As we continue to unravel the complexities of CTC biology and refine their clinical applications, the promise of improved cancer care and patient outcomes becomes increasingly tangible.

[outsizeclothes.com] 04/4/2024 13:27

Timing-wise next week should allow for presenting a better picture: - when the b&b and tax-losses sellers are out of the way you can afford to make announcements that could drive the share price.

[bones699] 04/4/2024 07:44

What you mean the share price on this pos nose dives faster oh ffs I was hedging my bets on a 10p placement!

[atmysignal] 04/4/2024 07:43

Start of reversal today

[bones699] 04/4/2024 07:00

Any news on further FDA approvals for cancer testing without which Parsortix is going nowhere fast?

Assume not lol!

[waterloo01] 03/4/2024 22:30

Interesting find.

[5oletrader] 03/4/2024 21:03

Today AN responded with these words - very interesting?-• Love your triple crown terminology: "triple-crown: (A) clear differentiation of BPH vs PCa, (B) excellent PCa risk stratification correlation w/ TNM or Gleason Score, (C) assessing PCa metastasis."• We are working on this also with the #Parsortix system analysing CTCs and have a great collaboration with solarishealthpartners.com. Living cancer cells (CTCs) are directly correlated to the triple crown!-This was in reply to the below:• Prostate cancer (PCa) is the 2nd most common cancer for men after lung cancer (est. 300K new US cases in 2024*). And PCa when diagnosed w/ distant metastases, the 5-yr survival is only 30%. The challenges are: (1) the current PSA test has very poor specificity (most cases are BPH), (2) prostate biopsy has major issues w/ complications and diagnostic yield, (3) critical needs of differentiating BPH vs PCa plus robust PCa risk stratification. Several PCa tests have now been developed to provide differential diagnosis before biopsy (one of these is an exosome-based assay and the only FDA-approved EV Dx test today). • Interestingly, many EV PCa studies have already explored various EV-associated biomarkers such as proteins, miRNA, mRNA, lncRNA, ... ... But I'll focus on ev PSMA here as ev PSMA is an excellent biomarker for PCa. Several PSMA-targeting nuclear medicines (Locametz and Pluvicto) have also been FDA-approved. • Here is a very interesting ev PSMA study (ref 1), and *while this was not done on Simoa*, I thought it is a very nice proof-of-concept study, and there are several good takeaways. In this study, the researchers first profiled PSMA+ EVs in PCa tissue, and the correlation with PCa risk stratification looks great here. For the plasma ev PSMA assay, the researchers isolated EVs first and then quantified the PSMA level. The plasma ev PSMA assay showed good Dx performance against BPH (sensitivity 91.7%, specificity 83.3%, AUC 0.94). However, PCa risk stratification does not look quite as strong as that for tissue PSMA+ EV profiling (see graph below).• Personally, I think an "ideal" PCa assay needs to hit the triple-crown: (a) clear differentiation of PCa vs BPH, (b) excellent PCa risk stratification correlation w/ TNM or Gleason Score, (c) assessing PCa metastasis. So here are my EV thoughts:• (1) 1st of all, a one-step Simoa EV assay could greatly simplify the workflow and improve assay performance (e.g., PCa risk stratification). A multi-step assay workflow could lose some information fidelity, plus there are additional QC/logistics challenges for clinical implementation. • ?(2) Secondly, one could run a multiplexing Simoa EV assay, including additional biomarkers (e.g., ev EphA2) to assess tumor aggressiveness and metastatic status.• A "triple-crown" PCa test will obviously have huge values for clinical Dx, and it could also aid prostate cancer drug development in clinical trials (Tx response, clinical outcome, etc.). So, anyone interested? • Study:Https://media.licdn.com/dms/image/D5622AQF1_2hWmJS33Q/feedshare-shrink_2048_1536/0/1712152090808?e=2147483647&v=beta&t=2CL8cDvVS30bQOZx6B-N9eLlm8NPSq7aNen3HiQLf1o-The above post was by:• Byron Shen, PhD MBA has a diverse and extensive work experience in the healthcare and life sciences industry. Byron currently serves as the Director of Business Development for Quanterix, where they focus on strategic initiatives and partnerships in the oncology space.-Company - QUANTERIX:• Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. Our digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. Our technology is currently being used for research applications across several therapeutic areas, including neurology, oncology, cardiology, inflammation and infectious disease.Https://www.quanterix.com/simoa-technology/

[jackdaw4243] 03/4/2024 16:10

Hav
After the bread and breakfast against and all my instincts I may see it as good entry point haveing had BA Systems cover my losses.

[outsizeclothes.com] 03/4/2024 16:00

The 100k buy just now at 12.1 is me.

[havinthelasttoast] 03/4/2024 15:52

The mugs here are happy with 85 percent loss. Better than 100
Lol

[jackdaw4243] 03/4/2024 15:42

My approach as been to register the losses before the new taxyear and realise some profits. I was/am -85% down on a 10K holding in AGL

Sipp up 35% this year so not all bad.

[adw198] 03/4/2024 14:30

3 months since a meaningful RNS so really need to deliver something. We know it has capacity to make big moves when news does land.

[waterloo01] 03/4/2024 14:23

Indeed he does. About time a major partnership was announced (wishful thinking?).

[bagpuss67] 03/4/2024 12:43

If you have a short position you do need to exercise some caution at this point as AN does have form for conjuring up something that sounds decent at the time to accompany the results

[davemac3] 03/4/2024 10:52

Didn’t Newland say this was worth £8 ? Was that per share or in total?

[havinthelasttoast] 03/4/2024 10:41

Wonder will it be a 10p placing or a 5p placing.

Mrs Newland Porsche is ordered so I imagine it’s soon.

[havinthelasttoast] 03/4/2024 10:40

Hahahahha

Rampers eh, got to laugh at ya

[htrocka2] 03/4/2024 10:31

Losing a bit of cash supporting this company is one thing but throwing your life away as a narcistic troll is by far, far the greater loss.....however, it's your life.

[mesquida] 03/4/2024 10:22

Good point ROBIZM

[robizm] 03/4/2024 10:16

So why are you wasting your valuable time posting on Aim companies?

[havinthelasttoast] 03/4/2024 09:46

Correct. 95 percent never make their shareholders any long term main.

[riskyinvestor] 03/4/2024 09:37

The AIM Market is a Con Market

After years of investing on it have finally realised it

Companies just like doing Placing and Placing and hardly ever create shareholder value.

[bones699] 02/4/2024 23:00

Reality check you bought a f@@king stale doughnut worth less than 10p!